MIDAZOLAM INJECTION USP 5 MG — DIN 02382350
MIDAZOLAM : 5 MG · PFIZER CANADA ULC · SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is MIDAZOLAM INJECTION USP?
MIDAZOLAM INJECTION USP 5 MG contains MIDAZOLAM : 5 MG. It is listed in the Health Canada Drug Product Database under DIN 02382350, held by PFIZER CANADA ULC, supplied as SOLUTION for INTRAMUSCULAR ; INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 25-Oct-2017. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is MIDAZOLAM INJECTION USP used for?
IM premedication; IV sedation/anxiolysis/amnesia for short procedures; induction of anesthesia; continuous IV infusion for sedation in mechanically ventilated ICU patients.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Midazolam cost around the world?
Midazolam is listed on 19 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Bahrain publishes a retail (max); Brazil publishes a preco fabrica (ex-factory ceiling). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| South Africa | single exit price | 22 | 29 | ZAR███.██ |
| United States | acquisition | 5 | 18 | USD███.██ |
| Brazil | preco fabrica (ex-factory ceiling) | 5 | 16 | BRL███.██ |
| Czechia | max producer price (ex-factory) | 5 | 16 | CZK███.██ |
| Romania | max producer price | 11 | 15 | RON███.██ |
| Saudi Arabia | public | 11 | 15 | SAR███.██ |
| Sweden | AIP (pharmacy purchase price) | 2 | 10 | SEK███.██ |
| Australia | ex-manufacturer | 2 | 9 | AUD███.██ |
| Italy | prezzo al pubblico (classe A) | 8 | 8 | EUR███.██ |
| Italy | ex-factory (classe H) | 6 | 8 | EUR███.██ |
| United Kingdom | hospital | 7 | 7 | GBP███.██ |
| Greece | producer price (ex-factory) | 7 | 7 | EUR███.██ |
| United Arab Emirates | public | 5 | 5 | AED███.██ |
| Morocco | PPV (public price) | 3 | 5 | MAD███.██ |
| Norway | max AUP (pharmacy retail) | 2 | 5 | NOK███.██ |
| Spain | PVP con IVA (public price) | 4 | 4 | EUR███.██ |
| Hungary | producer price (ex-factory) | 4 | 4 | HUF███.██ |
| Luxembourg | reimbursement | 4 | 4 | EUR███.██ |
| Slovakia | categorised final price | 4 | 4 | EUR███.██ |
| Bahrain | retail (max) | 1 | 2 | BHD███.██ |
191 pack listings across 118 brand entries and 18 price bases, refreshed 08 Sep 2026. Ranges span every Midazolam pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Midazolam in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
13 holders have a Canadian DIN containing Midazolam, across 32 DINs, of which 14 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| PFIZER CANADA ULC | 6 | 4 | MIDAZOLAM INJECTION, MIDAZOLAM INJECTION USP | Sourceable in Canada |
| NEURAXPHARM PHARMACEUTICALS, S.L. | 4 | 4 | BUCCOLAM | Sourceable in Canada |
| SANDOZ CANADA INCORPORATED | 4 | 2 | MIDAZOLAM INJECTION, MIDAZOLAM INJECTION SDZ | Sourceable in Canada |
| FRESENIUS KABI CANADA LTD | 2 | 2 | MIDAZOLAM INJECTION, USP | Sourceable in Canada |
| HIKMA CANADA LIMITED | 1 | 1 | MIDAZOLAM INJECTION USP | Sourceable in Canada |
| STERINOVA INC. | 1 | 1 | MIDAZOLAM INJECTION USP | Sourceable in Canada |
| APOTEX INC | 2 | 0 | APO-MIDAZOLAM INJECTABLE 1 MG/ML, APO-MIDAZOLAM INJECTABLE 5 MG/ML | No marketed DIN |
| BAXTER CORPORATION | 2 | 0 | MIDAZOLAM INJECTION, USP | No marketed DIN |
| HOFFMANN-LA ROCHE LIMITED | 2 | 0 | VERSED INJ 1MG/ML, VERSED INJ 5MG/ML | No marketed DIN |
| HOSPIRA HEALTHCARE ULC | 2 | 0 | MIDAZOLAM INJECTION BP | No marketed DIN |
| MYLAN PHARMACEUTICALS ULC | 2 | 0 | MIDAZOLAM INJECTION | No marketed DIN |
| PHARMASCIENCE INC | 2 | 0 | PMS-MIDAZOLAM | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 5 MG |
|---|---|
| Dosage form | SOLUTION |
| Route | INTRAMUSCULAR ; INTRAVENOUS |
| Pack configuration (monograph) | Not explicitly detailed in provided text (mentions 1 mg/mL and 5 mg/mL formulations). |
| Storage | Compatible and stable for 24 hours when diluted with 5% Dextrose or 0.9% Sodium Chloride. (Specific temperature range not in text). |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Midazolam |
|---|---|
| ATC code | N05CD08 |
| AHFS class | 28:24.08 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02382350 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2382350 |
| Brand name | MIDAZOLAM INJECTION USP |
| Generic / active ingredient | MIDAZOLAM : 5 MG |
| Market authorization holder | PFIZER CANADA ULC |
| Health Canada schedule | TARGETED SUBSTANCES (CDSA IV) |
| ATC code | N05CD08 |
| ATC anatomical main group | N — Nervous system |
| ATC therapeutic subgroup | N05CD |
| Current status | MARKETED |
| Status date | 25-Oct-2017 |
| Original market date | 2016-02-09 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Individualize dose. Administer slowly over 2-3 minutes for sedation. IM: 0.07-0.08 mg/kg. IV Sedation: 1-2.5 mg initially. ICU: 0.01-0.03 mg/kg/hr infusion. Titrate to effect.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to benzodiazepines; acute pulmonary insufficiency; severe COPD; acute narrow angle glaucoma. IV sedation is contraindicated in elderly/debilitated patients outside the ICU.
Warnings and precautions
Serious cardiorespiratory events (respiratory depression, arrest); risk of addiction, abuse, and misuse; life-threatening withdrawal symptoms; risks from concomitant use with opioids.
Is Midazolam in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by FRESENIUS KABI CANADA LTD, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
14 of 32 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| BUCCOLAM | 5 MG / 1 ML | SOLUTION | NEURAXPHARM PHARMACEUTICALS, S.L. | MARKETED | 02559587 |
| BUCCOLAM | 7.5 MG / 1.5 ML | SOLUTION | NEURAXPHARM PHARMACEUTICALS, S.L. | MARKETED | 02559595 |
| BUCCOLAM | 2.5 MG / 0.5 ML | SOLUTION | NEURAXPHARM PHARMACEUTICALS, S.L. | MARKETED | 02559579 |
| BUCCOLAM | 10 MG / 2 ML | SOLUTION | NEURAXPHARM PHARMACEUTICALS, S.L. | MARKETED | 02559609 |
| MIDAZOLAM INJECTION | 1 MG | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | 02240285 |
| MIDAZOLAM INJECTION | 5 MG | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | 02240286 |
| MIDAZOLAM INJECTION USP | 1 MG | SOLUTION | PFIZER CANADA ULC | MARKETED | 02382342 |
| MIDAZOLAM INJECTION USP | 5 MG | SOLUTION | PFIZER CANADA ULC | MARKETED | 02382385 |
| MIDAZOLAM INJECTION USP | 1 MG | SOLUTION | PFIZER CANADA ULC | MARKETED | 02382377 |
| MIDAZOLAM INJECTION USP | 1 MG | SOLUTION | STERINOVA INC. | MARKETED | 02498022 |
2 · Same class — other molecules in ATC N05CD
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Midazolam | APO-MIDAZOLAM INJECTABLE 1 MG/ML · APO-MIDAZOLAM INJECTABLE 5 MG/ML · BUCCOLAM · MIDAZOLAM INJECTION · MIDAZOLAM INJECTION BP · MIDAZOLAM INJECTION SDZ · MIDAZOLAM INJECTION USP · MIDAZOLAM INJECTION, USP · PMS-MIDAZOLAM · VERSED INJ 1MG/ML · VERSED INJ 5MG/ML | 32 | 14 | Yes |
| Temazepam | APO-TEMAZEPAM · CO TEMAZEPAM CAPSULES 15MG · CO TEMAZEPAM CAPSULES 30MG · DOM-TEMAZEPAM · GEN-TEMAZEPAM 15MG · GEN-TEMAZEPAM 30MG · NTP-TEMAZEPAM · PENTA-TEMAZEPAM CAPSULES · PHL-TEMAZEPAM · PMS-TEMAZEPAM · PMS-TEMAZEPAM - 15MG · PMS-TEMAZEPAM - 30MG · RATIO-TEMAZEPAM · RESTORIL · TEMAZEPAM · TEMAZEPAM-15 · TEMAZEPAM-30 · TEVA-TEMAZEPAM | 28 | 2 | Yes |
| Flurazepam | BIO-FLURAZEPAM · DALMANE · FLURAZEPAM · FLURAZEPAM 15 · FLURAZEPAM 15MG CAPSULE · FLURAZEPAM 30 · FLURAZEPAM 30MG CAPSULE · NOVO-FLUPAM CAP 15MG · NOVO-FLUPAM CAP 30MG · PMS-FLURAZEPAM CAP 15MG · PMS-FLURAZEPAM CAP 30MG · RIVA-FLURAZEPAM 15MG CAPSULES · RIVA-FLURAZEPAM 30MG CAPSULES · SOM-PAM · SOMNOL 15MG · SOMNOL 30MG | 20 | 2 | Yes |
| Nitrazepam | APO-NITRAZEPAM · MOGADON · NITRAZADON · NITRAZEPAM-10 · NITRAZEPAM-5 · SANDOZ NITRAZEPAM | 10 | 2 | Yes |
| Triazolam | ALTI-TRIAZOLAM TAB 0.125MG · ALTI-TRIAZOLAM TAB 0.25MG · HALCION · MYLAN-TRIAZOLAM · NOVO-TRIOLAM TAB 0.125MG · NOVO-TRIOLAM TAB 0.25MG · PENTA-TRIAZOLAM TABLETS · TRIAZOLAM · TRIAZOLAM TAB 0.125MG · TRIAZOLAM TAB 0.25MG · TRIAZOLAM TABLETS 0.125MG · TRIAZOLAM TABLETS 0.25MG | 16 | 1 | Yes |
| Estazolam | PROSOM TAB 1MG · PROSOM TAB 2MG | 2 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC N05C
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| N05CF | Eszopiclone · Zaleplon · Zolpidem · Zopiclone | 125 | 57 |
| N05CM | Dexmedetomidine · Ethchlorvynol · Scopolamine · Valerianae Radix | 31 | 11 |
| N05CC | Chloral Hydrate · Paraldehyde | 9 | 1 |
| N05CJ | Daridorexant · Suvorexant | 6 | 1 |
| N05CA | Amobarbital · Barbiturates, Plain · Pentobarbital · Secobarbital | 14 | 0 |
| N05CB | Combinations Of Barbiturates | 2 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is MIDAZOLAM INJECTION USP called?
The same molecule, Midazolam, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| BUCCOLAM | Latin | Czechia, Sweden |
| Dormicum | Latin | Czechia, Morocco, South Africa |
| MIDAZOLAM | Latin | Brazil |
| Midazolam Kalceks | Latin | Bahrain, Czechia, Saudi Arabia |
| Zyamis | Latin | Australia |
| Midanium | Latin | Morocco, South Africa |
| MIDAZOLAM ACCORD | Latin | Czechia |
| Midazolam Medical Valley | Latin | Sweden |
| Midazolam Panpharma | Latin | Norway |
| DORMIUM | Latin | Brazil |
| MIDAZOLAM HAMELN | Latin | Czechia |
| DORMONID | Latin | Brazil |
| Oroxelam | Latin | Saudi Arabia |
| HYPOZAM | Latin | Brazil |
| Micro-Midazolam | Latin | South Africa |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.